Spruce Biosciences Q1 EPS $(0.28) Beats $(0.29) Estimate, Sales $2.02M Beat $1.16M Estimate
Portfolio Pulse from Benzinga Newsdesk
Spruce Biosciences reported Q1 EPS of $(0.28), surpassing the $(0.29) estimate, and sales of $2.02M, exceeding the $1.16M estimate. This represents a 30% decrease in losses and a 2.85% increase in sales year-over-year.

May 13, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spruce Biosciences exceeded Q1 EPS and sales estimates, showing significant improvement over last year's figures.
Beating both EPS and sales estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. The significant improvement in financial performance compared to the previous year further strengthens the case for a positive impact on SPRB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100